Probiotic Solution for Pediatric Atopic Dermatitis
KEY MARKETING ASPECTS
- targeting the most frequent allergic disease in children
- unique combination of patented probiotic strains selected for the treatment of atopic dermatitis and for restoring the allergic immune system
- plus vitamin D – health claim related to the normal function of the immune system and inflammatory response (eU no 432/2012)
- 50% less allergy symptoms (pruritus, sleep loss, redness, swelling)
- less emotional stress
- alternative or add-on therapy to corticosteroids
- clinically tested in children
- high acceptance in children
- most efficient probiotic solution available for the treatment of atopic dermatitis
- pharmacy exclusive
Facts
- randomized, placebo-controlled clinical trial (RCT) demonstrating significant reduction in clinical symptoms of atopic dermatitis in children1
- additional 3 RCTs published demonstrating improvements of other allergy symptoms2,3,4
- vitamin D modulates the immune response and helps alleviating symptoms of atopic dermatitis5
- stimulating the Th1 immune response (Inf-γ)6 and reducing key mediators (IL-4 & Ige) of allergic response1
- highest clinical efficacy of probiotic treatments for dermatitis7
HOW TO USE
- lozenge: children above 3 years of age
- sachet: children under 3 years of age
- once a day
- add-on to emollient & topical corticosteroids
References
- Wang & Wang, Clin exp Allergy (2015)
- Costa et al., eur J Clin nutr (2014)
- Peng et al., Pediatr Allergy Immunol (2005)
- Wang et al., Pediatr Allergy Immunol (2004),
- Mutgi & Koo, Pediatr Dermatol (2013)
- Lu et al., eP 2,581,461B1 (2011)
- Huang et al., front Cell Infect Microbiol 7 (2017)
Dermazyn is a registered trademark by BLUESTONE PHARMA GmbH | contact: info@bluestone-pharma.com